 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...2122232425262728293031...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) - Aug 18, 2021
P3, N=240, Recruiting, Sponsor: JHSPH Center for Clinical Trials
Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- || Avastin (bevacizumab) / Roche
Clinical, Retrospective data, Journal: Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. (Pubmed Central) - Aug 17, 2021
No significant differences between the 3 anti-VEGF molecules were recorded in wet-AMD patients in real-life conditions. Despite the long-term therapy, we found a slight reduction in visual function especially after the third year of treatment.
- ||||||| Lytenava (bevacizumab-vikg) / Outlook Therap
Trial completion: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Aug 13, 2021
P3, N=227, Completed, Sponsor: Outlook Therapeutics, Inc.
Despite the long-term therapy, we found a slight reduction in visual function especially after the third year of treatment. Active, not recruiting --> Completed
- |||||||||| HLX04-O (bevacizumab biosimilar) - Fosun Pharma, Essex Bio / Technology
New P3 trial: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD (clinicaltrials.gov) - Aug 11, 2021
P3, N=388, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: REBEL: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema (clinicaltrials.gov) - Aug 4, 2021
P4, N=56, Not yet recruiting, Sponsor: Cairo University
- | Lucentis (ranibizumab) / Roche, Novartis
New trial: Analysis of na (clinicaltrials.gov) - Aug 3, 2021
P, N=34, Recruiting, Sponsor: Brugmann University Hospital
- | Lucentis (ranibizumab) / Roche, Novartis
New trial: PAMER: Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment (clinicaltrials.gov) - Jul 28, 2021
P, N=50, Completed, Sponsor: Centre Hospitalier R
- |||||| HLX04-O (bevacizumab biosimilar) - Fosun Pharma, Essex Bio / Technology
Enrollment open: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD (clinicaltrials.gov) - Jul 28, 2021
P3, N=388, Recruiting, Sponsor: Shanghai Henlius Biotech
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration. (Pubmed Central) - Jul 28, 2021
Difference was statistically not significant for any endpoint at 16 and 24 weeks for the primary and secondary endpoints. The evaluation of efficacy, safety and immunogenicity was concluded to show no meaningful clinical difference for biosimilar ranibizumab with the reference product.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Lucentis (ranibizumab) / Roche, Novartis
Journal: A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. (Pubmed Central) - Jul 24, 2021
Furthermore, using a laser-induced choroidal neovascularization (CNV) model, we observed that the combined treatment of anlotinib and Lucentis reduced the size and thickness of CNV lesions compared to Lucentis monotherapy alone. Taken together, our results suggest that anlotinib could be a promising drug candidate for ocular neovascularization.
- ||||| Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
Enrollment closed: XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) - Jul 23, 2021
P3, N=580, Active, not recruiting, Sponsor: Xbrane Biopharma AB
Taken together, our results suggest that anlotinib could be a promising drug candidate for ocular neovascularization. Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma. (Pubmed Central) - Jul 23, 2021
The conbercept effects were similar with that of ranibizumab. Intravitreal injection of conbercept was effective for NVG treatment, which provides a new therapeutic drug for NVG treatment.
- ||||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov) - Jul 23, 2021
P3, N=545, Active, not recruiting, Sponsor: Hoffmann-La Roche
Intravitreal injection of conbercept was effective for NVG treatment, which provides a new therapeutic drug for NVG treatment. Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. (Pubmed Central) - Jul 22, 2021
Dry macula was noted in 1 vs 14 eyes in group R vs group A. After treating refractory DME with initial bevacizumab injections, 3 injections of either aflibercept or ranibizumab had similar anatomic and functional outcomes. Aflibercept achieved dry macula in more eyes with refractory DME compared to ranibizumab.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study. (Pubmed Central) - Jul 21, 2021
Aflibercept achieved dry macula in more eyes with refractory DME compared to ranibizumab. No abstract available
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: PROGRESSION OF RETINAL ISCHEMIA IN A CASE OF MACULAR TELANGIECTASIA TYPE 1 AFTER RANIBIZUMAB INJECTION: OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS. (Pubmed Central) - Jul 18, 2021
No abstract available Optical coherence tomography angiography may represent an indispensable diagnostic technique, complementary to traditional imaging, in the evaluation of the effects of anti-vascular endothelial growth factor therapy in patients with MacTel Type 1.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Case Report: Acute Retinal Necrosis after Intravitreal Ranibizumab for Exudative Macular Degeneration. (Pubmed Central) - Jul 18, 2021
Therefore, early detection of viral DNA in the intraocular fluid using polymerase chain reaction is recommended. Immediate antiviral treatment may be beneficial to prevent severe visual loss.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Polypoidal choroidal vasculopathy in Canada. (Pubmed Central) - Jul 17, 2021
Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Non-Damaging Retinal Laser Therapy in Recurrent Diabetic Macular Edema after Anti-VEGF injections. (Pubmed Central) - Jul 13, 2021
However, CFT and BCVA outcomes after NRT were inferior to those achieved after previous ranibizumab treatment. No positive effect of NRT was not observed in patients with moderate and severe macular edema in DME treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials. (Pubmed Central) - Jul 11, 2021
Central RVO patients treated with dexamethasone received more laser treatments over the 6 months than those treated with ranibizumab, while there was no difference in the frequency of laser therapy between the branch RVO treatment groups. VA gain over six months in ranibizumab-treated RVO patients is not affected by ischemia, and is associated with less development of new ischemia during the first 6 months of treatment and equal or fewer laser treatments than dexamethasone implant.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion. (Pubmed Central) - Jul 11, 2021
VA gain over six months in ranibizumab-treated RVO patients is not affected by ischemia, and is associated with less development of new ischemia during the first 6 months of treatment and equal or fewer laser treatments than dexamethasone implant. Intravitreal administration of anti-vascular endothelial growth factor did not significantly increase the risks of cardiovascular events, hypertension or heart rate disorders in retinal vein occlusion patients.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment. (Pubmed Central) - Jul 10, 2021
P=N/A
Intravitreal administration of anti-vascular endothelial growth factor did not significantly increase the risks of cardiovascular events, hypertension or heart rate disorders in retinal vein occlusion patients. Microperimetry and mfERG were able to demonstrate DMO functional improvement after treatment loading dose, as well as early visual changes when treatment regimen was switched to PRN.
- ||| Lucentis (ranibizumab) / Roche, Novartis
⛓تابع التغريدة أعلاه شركة روش @Roche سلّمت هيئة الغذاء والدواء الأمريكية @US_FDA وهيئة الدواء الأوروبية @EMA_News طلب اعتماد لاختراعها: PDS الذي يعبأ بدواءranibizumabلعلاج ضمور الشبكية العمريnAMD، كبديل لحقنة💉العين👁 ✅قرار الاعتماد/الرفض في أكتوبر https://t.co/yCHQEBF6SU (٢) (Twitter) - Jul 9, 2021
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: A case of late-onset larynx angioedema after ranibizumab intravitreal injection: Ranibizumab-related angioedema. (Pubmed Central) - Jul 9, 2021
In occasion of the second intravitreal injection, video rhinofibrolaryngoscopy revealed subglottic edema that resolved within few hours by betamethasone 4 mg intramuscular injection. This report suggests that, even in cases of intravitreal injection, patients with history of allergy, despite the anti-allergic treatment, should be hospitalized to detect late onset of such a life-threatening complication.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab(PDS) for Patients With Neovascular AMD () - Jul 8, 2021 - Abstract #COS2021COS_424;
P3
The PDS phase 3 Archway trial met its primary endpoint and demonstrated that PDS 100 mg/mL Q24W treatment resulted in vision outcomes at W36/W40 that were equivalent to RBZ 0.5 mg Q4W injections with ~5-times fewer treatments. The PDS was generally well tolerated with a favorable benefit-risk profile.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Faricimab in Neovascular Age-Related Macular Degeneration: One-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials () - Jul 8, 2021 - Abstract #COS2021COS_303;
P3
In phase 2 studies, faricimab Q4W or Q8W were associated with robust vision and anatomic improvements that were comparable to ranibizumab Q4W (AVENUE), and faricimab Q12W or Q16W demonstrated sustained efficacy and durability over 1 year (STAIRWAY). TENAYA and LUCERNE evaluate the safety, efficacy, and durability of an extended (up to Q16W) dosing regimen for intravitreal faricimab in patients with nAMD.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): 1-Year results from Phase 3 YOSEMITE and RHINE Trials () - Jul 8, 2021 - Abstract #COS2021COS_302;
P3
YOSEMITE and RHINE evaluate the safety, efficacy, and durability of faricimab in patients with DME using PTI, a protocol-driven regimen based on treat-and-extend, or Q8W dosing. Year-1 results will be presented at the meeting.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment switch from aflibercept to ranibizumab in Canadian DME patients in a real-world setting: the PRECISE study 237 () - Jul 8, 2021 - Abstract #COS2021COS_301;
Data from enrolled patients analyzed thus far showed that the key reason for treatment switch to RBZ-PFS was lack of response to aflibercept treatment, primarily due to presence of fluid in the macula. Preliminary results from completers demonstrated a reduction in CRT, with maintenance of visual acuity and safety.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. (Pubmed Central) - Jul 7, 2021
Preliminary results from completers demonstrated a reduction in CRT, with maintenance of visual acuity and safety. These results demonstrate the effectiveness and safety of ranibizumab in treatment-naive neovascular age-related macular degeneration patients.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Monotherapy: RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY. (Pubmed Central) - Jul 7, 2021
Retinopathy of prematurity recurrence requiring re-treatment was encountered as late as 50 weeks of postmenstrual age after IVB or IVR but earlier after laser. Longer follow-up for infants treated with anti-vascular endothelial growth factor is needed, especially in patients with significant risk factors such as an early postmenstrual age at initial treatment, Zone I ROP, low Apgar score, and multiple births.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study. (Pubmed Central) - Jul 7, 2021
Longer follow-up for infants treated with anti-vascular endothelial growth factor is needed, especially in patients with significant risk factors such as an early postmenstrual age at initial treatment, Zone I ROP, low Apgar score, and multiple births. At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naïve nAMD.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol. (Pubmed Central) - Jul 7, 2021
At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naïve nAMD. The simultaneous addition of DEX implant at any time during the three monthly loading doses of ranibizumab in patients with DMO significantly improved the visual outcomes and revealed superior anatomic outcomes than those with the ranibizumab monotherapy.
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: Pre-therapeutic Biomarkers for Ranibizumab Therapy among Type 2 Diabetic Patients with Diabetic Macular Edema. (Pubmed Central) - Jul 7, 2021
The simultaneous addition of DEX implant at any time during the three monthly loading doses of ranibizumab in patients with DMO significantly improved the visual outcomes and revealed superior anatomic outcomes than those with the ranibizumab monotherapy. The present study postulates that diffuse diabetic macular edema with proliferative diabetic retinopathy and baseline circulatory soluble VEGF receptor 2 may be potential candidates as therapy-stratifying markers for ranibizumab treatment among patients with diabetic macular edema.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Case Report: Alagille Syndrome Presenting with Angioid Streaks. (Pubmed Central) - Jul 7, 2021
Alagille syndrome has many ophthalmic manifestations, most of them benign with minimal threat to vision. Herein for the first time, we present a case of Alagille syndrome with angioid streak-related choroidal neovascularization, which resulted in severe vision loss.
- | zifibancimig (RG6120) / Roche
Trial completion date, Trial primary completion date: BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jul 7, 2021
P1, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Herein for the first time, we present a case of Alagille syndrome with angioid streak-related choroidal neovascularization, which resulted in severe vision loss. Trial completion date: Mar 2026 --> Nov 2025 | Trial primary completion date: Mar 2026 --> Nov 2025
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Human Platelets Take up Anti-VEGF Agents. (Pubmed Central) - Jul 6, 2021
Clathrin-coated vesicles seem to be more prominent in the transport of bevacizumab than ranibizumab and aflibercept. Nevertheless, whether the different localization and transport of bevacizumab are truly related to specific differences of receptor-mediated endocytosis has to be revealed by further research.
- | Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration. (Pubmed Central) - Jul 4, 2021
Nevertheless, whether the different localization and transport of bevacizumab are truly related to specific differences of receptor-mediated endocytosis has to be revealed by further research. A single Brolucizumab injection was able to determine the short-term effects on PEDs' anatomical features of eyes with an unresponsive e-AMD.
- || Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. (Pubmed Central) - Jul 4, 2021
Treatment was terminated early in five eyes (two intraocular inflammations with vascular occlusion without vision loss, one stroke, and two changes in the treatment plan). Improvement in visual performance and longer treatment intervals in our series over 6 months indicate the potential of brolucizumab to reduce the treatment burden in nAMD, while two instances of intraocular inflammation were encountered.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization. (Pubmed Central) - Jul 3, 2021
A retrospective cohort analysis of treatment naive patients with myopic CNV who received treatment with either intravitreal ranibizumab or aflibercept over a 12-year period from September 2007 to May 2020 was performed...Younger age is associated with a better final visual outcome. These findings may help to advise patients about the prognosis of treatment and help guide treatment decisions.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy. (Pubmed Central) - Jul 2, 2021
These findings may help to advise patients about the prognosis of treatment and help guide treatment decisions. In PNV, choroidal thickness significantly decreases with anti-VEGF therapy, resembling a "vanishing pachy-choroid", and thus does not represent a valid long-term diagnostic criterium, especially when differentiating PNV from nAMD.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion. (Pubmed Central) - Jul 2, 2021
The level of AH inflammatory cytokines was significantly associated with the ischemic status of the retina, treatment outcomes, and SCT in BRVO ME patients. Thick baseline SCT might be a predictive sign for better treatment outcomes in BRVO ME patients which are thought to be related to a higher level of intraocular inflammatory cytokines in these patients.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Comparison of the effects of intravitreal ranibizumab and aflibercept on retinal vessel diameters in patients with diabetic macular edema. (Pubmed Central) - Jul 2, 2021
Thick baseline SCT might be a predictive sign for better treatment outcomes in BRVO ME patients which are thought to be related to a higher level of intraocular inflammatory cytokines in these patients. Both intravitreal ranibizumab and aflibercept agents cause a significant narrowing in the retinal vessel diameters in patients with DME after three loading doses at monthly intervals.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results. (Pubmed Central) - Jul 1, 2021
Both intravitreal ranibizumab and aflibercept agents cause a significant narrowing in the retinal vessel diameters in patients with DME after three loading doses at monthly intervals. Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, HEOR: Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - Jun 30, 2021
P3
Substantial reductions in anti-vascular endothelial growth factor cost may make the ranibizumab therapy cost-effective within this range even for patients without baseline CI-DME. ClinicalTrials.gov identifier: NCT01489189.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. (Pubmed Central) - Jun 30, 2021
The incidence rate of endophthalmitis in the group with topical antibiotic prophylaxis after intravitreal injection was similar to the group with no prophylaxis. Changing the current clinical practice to no antibiotic prophylaxis had no effect on the incidence of endophthalmitis.
- || Beovu (brolucizumab-dbll) / Novartis, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, PK/PD data, Journal: Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes. (Pubmed Central) - Jun 30, 2021
A PK model simulated Cvm after single-dose IVT-AFL, IVT-BRO, and ranibizumab (IVT-RAN), and extrapolated intraocular VEGF-suppression thresholds and durations...The PK-modeled mean VEGF-suppression duration for IVT-BRO was substantially shorter than that published for IVT-AFL and may not be sufficient to effectively suppress VEGF throughout q12w dosing. The PK modeling suggests that more patients may be maintained on ≥q12w dosing with IVT-AFL than with IVT-BRO.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Jun 30, 2021
A composite score based on seven patient characteristics prior to treatment could be used to discriminate patients with predicted insufficient response to anti-vascular endothelial growth factor treatment. The method could be used to create a virtual ranibizumab treatment arm in clinical trials or to reduce the size of a ranibizumab active control arm.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinal pigment epithelial tear in age-related macular degeneration (Pubmed Central) - Jun 30, 2021
Continuous monitoring and adherence to anti-VEGF therapy leads to better anatomical and functional results in the long term, which is crucial for improving the quality of life of patients with age-related macular degeneration. This article reviews the literature and presents current data on RPET, identifies risk factors and mechanisms of its development, provides classification, and describes modern options for its diagnosis and treatment.
- Humira (adalimumab) / Eisai, AbbVie, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Complications After Dental Extractions in Patients Taking Biologic Agents () - Jun 29, 2021 - Abstract #IASP2021IASP_971;
Orofacial adverse effects of biologic agents, including oral lesions and development of orofacial infections, have primarily been reported through case reports and case series. The impact of biologic agents on provision of and recovery after dental treatment remains unknown.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Association between Ranibizumab Injections and Risk of Acute Myocardial Infarction in Age-related Macular Degeneration: A Case-crossover Study. (Pubmed Central) - Jun 24, 2021
The impact of biologic agents on provision of and recovery after dental treatment remains unknown. Intravitreal ranibizumab injection does not appear to increase the risk of hospitalization for AMI within 60 days in exudative AMD patients.